FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections

This article was originally published here

“The FDA’s decision supports our ability to provide a new treatment option for critically ill COVID-19 patients with bacterial infections resistant to nearly all other available therapies. This

The post FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply